Gilead Reports real-world evidence Data for Antisense oligonucleotide in Multiple myeloma

Gilead today announced real-world evidence results for antisense oligonucleotide in patients with multiple myeloma. The study demonstrated that antisense oligonucleotide achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of multiple myeloma and support the continued development of antisense oligonucleotide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.